Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
EL
Enliven Therapeutics, Inc. Common Stock
ELVN
Mkt Cap
$2.73B
Volume
1.04M
Next Earnings
November 11th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
EL
ELVN
EL
Enliven Therapeutics, Inc. Common Stock
ELVN
News
·
Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight
Mkt Cap
$2.88B
Volume
1.04M
Next Earnings
November 11th
Chart
Financials
Earnings
News
About
Insider
Filings
Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight
The chronic myeloid leukemia (CML) clinical trial pipeline shows robust activity with 25+ pharmaceutical companies developing 25+ pipeline drugs. Key players including Merck, Enliven Therapeutics, ImmunoForge, and others are advancing promising therapies like TERN-701, ELVN-001, and KF1601 across various clinical stages. The market is evolving from established tyrosine kinase inhibitors toward newer selective agents targeting resistance, intolerance, and treatment-free remission.
GlobeNewswire Inc. · Sep 8, 2026
What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally
OrbiMed Advisors sold 860,123 shares of Enliven Therapeutics (ELVN) for approximately $39 million on June 22, 2026, representing 11.60% of its holdings. Despite the partial exit following a 130% stock rally, OrbiMed retains over 6.5 million shares, signaling continued confidence. Enliven, a clinical-stage biotech focused on cancer therapies, has a strong cash position of $452.4 million and recently closed a $460 million public offering to fund operations through mid-2029.
The Motley Fool · Jun 27, 2026
Medical Hedge Fund Sells 281,000 Shares of Enliven Theapeutics. Is it Time to Sell ELVN?
OrbiMed Advisors, a major shareholder owning over 10% of Enliven Therapeutics, sold 281,408 shares for approximately $12.7 million on June 15, 2026. Despite the company's recent positive Phase III leukemia drug trial data and 95% one-year stock price gain, the insider sale raises questions about whether the hedge fund views the recent rally as a peak opportunity to take profits, though the sale could also reflect routine portfolio rebalancing.
The Motley Fool · Jun 24, 2026
Enliven Therapeutics' Chief Medical Officer Sold 5,000 Company Shares. Here's What That Means for Investors.
Enliven Therapeutics' Chief Medical Officer Helen Collins sold 5,000 shares worth approximately $199,000 on May 18, 2026, as part of a pre-established Rule 10b5-1 trading plan. Despite the sale, Collins retains over 150,000 shares in the company, suggesting confidence in the biotech firm. The sale occurred during a period of strong stock performance, with the company up 135.2% over one year.
The Motley Fool · Jun 1, 2026
Enliven Posts Loss Beat and Cash Surge
Clinical-stage biotech Enliven Therapeutics reported Q2 2025 results, highlighting positive Phase 1 clinical data for ELVN-001 in chronic myeloid leukemia and a strengthened cash position of $490.5 million following a $230 million public offering.
The Motley Fool · Aug 13, 2025
Enliven Therapeutics, Inc. Is a Great Choice for 'Trend' Investors, Here's Why
Enliven Therapeutics (ELVN) is a good choice for trend investors due to its recent price increase, positive earnings estimate revisions, and strong fundamentals, making it a Zacks Rank #2 (Buy) stock.
Benzinga · Oct 14, 2024
Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
Enliven Therapeutics reported positive data from a Phase 1 trial of its drug ELVN-001for chronic myeloid leukemia, with a 44% major molecular response rate by 24 weeks and a favorable safety profile.
GlobeNewswire Inc. · Sep 28, 2024
Enliven Therapeutics COO sells over $1.25m in company stock - Investing.com
Anish Patel, the Chief Operating Officer of Enliven Therapeutics, has sold over $1.25 million worth of company stock in a series of transactions. The sales were conducted under a Rule 10b5-1 trading plan, and Patel remains a significant shareholder in the company.
Investing.com · Jul 16, 2024
Enliven Therapeutics to Present at Two Upcoming Investor Conferences
BOULDER, Colo., May 29, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that management will present at the following investor conferences in June:
GlobeNewswire Inc. · May 29, 2024
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
Announced positive proof of concept data from Phase 1 clinical trial of ELVN-001 in CML, achieving an initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients
GlobeNewswire Inc. · May 14, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
EL
ELVN
Enliven Therapeutics, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
ELVN
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any ELVN yet.
Related Tickers
Earnings